BUZZ - Corcept shares rise as its ovarian cancer drug shows positive results in mid-stage study

October 26 - ** Corcept Therapeutics (CORT.O) shares rose 3% in pre-market trading to $87.23

** The biotechnology company announced that its ovarian cancer drug Lifyorli, when combined with the chemotherapy drug nab-paclitaxel (albumin-bound paclitaxel) and bevacizumab, demonstrated positive effects in patients with platinum-resistant ovarian cancer

** The company added that in a study involving 95 patients, this treatment regimen achieved a median progression-free survival of 7.2 months and an objective response rate of 59%

** Patients who had not previously received bevacizumab treatment saw even better results, with a median progression-free survival of 8.1 months and an objective response rate of 66%—CORT

** Data showed that 88% of patients were still alive after 6 months; at the time of primary analysis, the median overall survival had not yet been reached

** As of the previous trading day’s close, the stock had risen about 147% year to date

(To assist non-native English speakers, Reuters offers automated translations of its reports in several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters does not accept any liability for any damage or loss caused by the use of the automated translation feature.)